| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2b data readout example | Phase 2b | — | Subscribe to access the data. | Small Molecules | Endocrine System | ||
Phase 2b data readout example | Phase 2b | — | Subscribe to access the data. | Small Molecules | Endocrine System | ||
Phase 2b data readout example | Phase 2b | — | Subscribe to access the data. | Small Molecules | Endocrine System |
Recent Updates
Recently added Catalysts
Ventyx Biosciences, Inc.$14
+0.01 (+0.07%)
D 37Pipeline Score Overvalued Pharma · Clinical
Market Cap
1.00 B
EPS
-1.50
P/E Ratio
-
Value Trade
76.26 M
SEC Financials
Q3 2025Dilution Risk
25%R&D Expenses
17.71 M
Total Assets
211.47 M
Total Liabilities
20.10 M
Equity
191.36 M
0.36 %
Week
0.29 %
1 Month
77.55 %
3 Month
444.75 %
6 Month
-24.93 %
5 Year
-24.93 %
All Time
Cash Data
Cash Position
192.64 M
Monthly Burn
8.29 M
Runway
14.4 mo
Burn Trend
SEC Filing
Nov 6, 2025
Overview
Volume
5.45 M
52 Week Range
0.78 - 25
% held by Insiders
12.9 %
% held by Institutions
75.92 %
Enterprise Value
822.04 M
Total Shares
71.71 M
Short %
9.48 %
Float Shares
51.27 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2024-12-31 | VTX2735 | Phase 2 data readout | Phase 2 | — | – | – | – |
2024-12-31 | VTX2735 | Phase 2 data readout | Phase 2 | — | – | – | – |
2024-12-31 | VTX2735 | Phase 2 data readout | Phase 2 | — | – | – | – |
Drug Pipeline Intelligence
D37
Pipeline Score $273M
Pipeline ValueOvervalued
Valuation Signal4
Drugs Scored0.3x
rNPV / MCap Top 54%
Micro Cap (rank 426 of 923)
Percentile RankVentyx Biosciences, Inc. faces pipeline headwinds (37/100), with $865M risk-adjusted pipeline value, led by VTX3232 Dose A in Obesity (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VTX3232 Dose A Small molecule | Obesity | Phase 2 | NCT06771115 | 23% | $559M | COMPLETED | 176 | - | - | Sep 10, 2025 | - | Nov 10, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
VTX3232 | Obesity and Cardiovascular Risk Factors | Phase 2 | 2025-10-22 | 78% reduction in hsCRP at week 12 relative to baseline; 64% reduction in hsCRP at week 12 relative to baseline; statistically significant reductions in IL-6 (p<0.0001); restored nearly 70% of study participants to target hsCRP levels of less than 2mg/L Read More | Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors Read More | |
VTX3232 | Obesity and Cardiovascular Risk Factors | Phase 2 | 2025-10-22 | 78% reduction in hsCRP at week 12 relative to baseline; 64% reduction in hsCRP at week 12 relative to baseline; statistically significant reductions in IL-6 (p<0.0001); restored nearly 70% of study participants to target hsCRP levels of less than 2mg/L Read More | Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors Read More | |
VTX3232 | Obesity and Cardiovascular Risk Factors | Phase 2 | 2025-10-22 | 78% reduction in hsCRP at week 12 relative to baseline; 64% reduction in hsCRP at week 12 relative to baseline; statistically significant reductions in IL-6 (p<0.0001); restored nearly 70% of study participants to target hsCRP levels of less than 2mg/L Read More | Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk Factors Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in VTYX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
VTYX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How VTYX ranks across every disease it competes inCompetitive Position is a premium feature
See how VTYX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial